Author
Friederike Holze
Other affiliations: University of Basel
Bio: Friederike Holze is an academic researcher from University Hospital of Basel. The author has contributed to research in topics: Medicine & Lysergic acid diethylamide. The author has an hindex of 8, co-authored 16 publications receiving 185 citations. Previous affiliations of Friederike Holze include University of Basel.
Topics: Medicine, Lysergic acid diethylamide, Placebo, Hallucinogen, Psilocybin
Papers
More filters
TL;DR: Investigation of the acute autonomic, subjective, and endocrine effects of single doses of LSD, MDMA, and d-amphetamine in 28 healthy subjects indicates clearly distinct acute effects and may assist the dose-finding in substance-assisted psychotherapy research.
116 citations
TL;DR: The LSD dose–response curve showed a ceiling effect for subjective good effects, and ego dissolution and anxiety increased further at a dose above 100 µg, which may assist with dose finding for future LSD research.
92 citations
09 Apr 2021
TL;DR: The finding that LSD acutely increases BDNF levels warrants studies in patient populations, based on preclinical evidence for psychedelic-induced neuroplasticity in humans.
Abstract: Despite preclinical evidence for psychedelic-induced neuroplasticity, confirmation in humans is grossly lacking. Given the increased interest in using low doses of psychedelics for psychiatric indi...
49 citations
TL;DR: Overall, the present study demonstrated selective, beneficial effects of low doses of LSD on mood and cognition in the majority of observations, and the minimal LSD dose at which subjective and performance effects are notable is 5 mcg and the most apparent effects were visible after 20 mcg.
44 citations
TL;DR: In this paper , a double-blind, randomized, placebo-controlled, crossover design was used in 28 healthy subjects (14 women, 14 men) who underwent five 25-hour sessions and received placebo, LSD (100 and 200 µg), and psilocybin (15 and 30 mg).
44 citations
Cited by
More filters
TL;DR: Investigation of the acute autonomic, subjective, and endocrine effects of single doses of LSD, MDMA, and d-amphetamine in 28 healthy subjects indicates clearly distinct acute effects and may assist the dose-finding in substance-assisted psychotherapy research.
116 citations
09 Apr 2021
TL;DR: Data is presented suggesting that the subjective effects induced by psychedelics may not be necessary to produce long-lasting changes in mood and behavior.
Abstract: Psychedelics represent one of the most promising classes of experimental medicines for the treatment of neuropsychiatric disorders due to their ability to promote neural plasticity and produce both rapid and sustained therapeutic effects following a single administration. Conventional wisdom holds that peak mystical experiences induced by psychedelics are a critical component of their therapeutic mechanisms of action, though evidence supporting that claim is largely correlational. Here, I present data suggesting that the subjective effects induced by psychedelics may not be necessary to produce long-lasting changes in mood and behavior. Understanding the role of subjective effects in the therapeutic mechanisms of psychedelics will have important implications for both basic neuroscience and for increasing patient access to the next generation of medicines developed as a result of psychedelic research.
108 citations
TL;DR: This review discusses 4 types of compounds: 3,4-methylenedioxymethamphetamine, ketamine, classical psychedelics (e.g., psilocybin and lysergic acid diethylamide), and cannabinoids, and describes the therapeutic rationale, the setting in which they are being administered, and their current state of evidence in the treatment of PTSD.
Abstract: There are few medications with demonstrated efficacy for the treatment of posttraumatic stress disorder (PTSD). Treatment guidelines have unequivocally designated psychotherapy as a first line treatment for PTSD. Yet, even after psychotherapy, PTSD often remains a chronic illness, with high rates of psychiatric and medical comorbidity. Meanwhile, the search for and development of drugs with new mechanisms of action has stalled. Therefore, there is an urgent need to explore not just novel compounds but novel approaches for the treatment of PTSD. A promising new approach involves the use of psychedelic drugs. Within the past few years, 2 psychedelics have received breakthrough designations for psychiatric indications from the US Food and Drug Administration, and several psychedelics are currently being investigated for the treatment of PTSD. This review discusses 4 types of compounds: 3,4-methylenedioxymethamphetamine, ketamine, classical psychedelics (e.g., psilocybin and lysergic acid diethylamide), and cannabinoids. We describe the therapeutic rationale, the setting in which they are being administered, and their current state of evidence in the treatment of PTSD. Each compound provides unique qualities for the treatment of PTSD, from their use to rapidly target symptoms to their use as adjuncts to facilitate psychotherapeutic treatments. Several questions are formulated that outline an agenda for future research.
100 citations
TL;DR: It is concluded that while most anecdotal reports focus on the positive experiences with microdosing, future research should also focus on potential risks of (multiple) administrations of a psychedelic in low doses, and (pre)clinical studies including biological as well as cognitive parameters have to be conducted to shed light on the potential negative consequencesmicrodosing could have.
Abstract: Background:In the past few years, the issue of ‘microdosing’ psychedelics has been openly discussed in the public arena where claims have been made about their positive effect on mood state and cog...
97 citations
TL;DR: The LSD dose–response curve showed a ceiling effect for subjective good effects, and ego dissolution and anxiety increased further at a dose above 100 µg, which may assist with dose finding for future LSD research.
92 citations